A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout

Trial Profile

A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs Lesinurad (Primary)
  • Indications Gout
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ardea Biosciences
  • Most Recent Events

    • 23 Sep 2017 Results related to this study and it's parent/core study (refer CTP: 212123) were published in the Rheumatology
    • 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2014 Planned End Date changed from 1 Jan 2016 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top